Dr. Drilon Discusses CNS Penetration in NSCLC

Alexander Drilon, MD
Published: Thursday, Nov 09, 2017



Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 
SELECTED
LANGUAGE


Alexander Drilon, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses central nervous system (CNS) penetration in the treatment of non-small cell lung cancer (NSCLC).

In general, NSCLC tumors like to metastasize to a CNS compartment, says Drilon. Now that tyrosine kinase inhibitors (TKIs) are being tested, it is important to focus on CNS penetration during new drug development.

Drilon says that investigators could take note from studies in ALK-rearranged disease, which has been testing drugs that successfully penetrate the CNS.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication
x